RBC Capital on PTC Therapeutics (PTCT): 'Data Should Be Good Enough for Translarna to Stay on EU Mkt'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $42.00 price target on PTC Therapeutics (NASDAQ: PTCT)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
